{"id":"W4365512324","doi":"10.1158/1538-7445.am2023-ct119","title":"Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with <i>FGFR3</i> alterations (trial in progress)","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Fibroblast growth factor receptor; Hyperphosphatemia; Mucositis; Fibroblast growth factor receptor 1; Cancer; Internal medicine; Cancer research; Oncology; Fibroblast growth factor; Receptor; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001070019,0.0002505794,0.0004033251,0.000991714,0.0001585995,0.00006118632,0.0004736056,0.0001532975,0.00002745951],"category_scores_gemma":[0.0002148024,0.0002313322,0.00005722964,0.002268542,0.0002970193,0.00003843693,0.0003148565,0.000798714,0.000009877072],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003323226,"about_ca_system_score_gemma":0.0008920787,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001563766,"about_ca_topic_score_gemma":0.02091728,"domain_scores_codex":[0.9962965,0.0002871884,0.000606509,0.0008255432,0.0009039402,0.001080354],"domain_scores_gemma":[0.9987329,0.00008959237,0.0001107894,0.0005187332,0.0003819304,0.0001660904],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.03494028,0.004763094,0.05420312,0.0003299604,0.00009319409,0.0003313939,0.002615121,0.0030524,0.8970377,0.00002196066,0.0009975364,0.00161417],"study_design_scores_gemma":[0.1301833,0.02754701,0.1433797,0.001039039,0.00001068549,0.000006482948,0.003833728,0.0003982141,0.6919969,0.0001481247,0.0006237386,0.0008330249],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957975,0.000146748,0.000002266117,0.0002486541,0.00005088667,0.003500755,0.00006706911,0.00001853855,0.000167604],"genre_scores_gemma":[0.9967095,0.00007756333,0.00002106909,0.000007260622,0.0001659429,0.002678392,0.0001030944,0.00006084825,0.0001763827],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2050409,"threshold_uncertainty_score":0.9969484,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03827723797424968,"score_gpt":0.4184666480959912,"score_spread":0.3801894101217415,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}